COEP
Price
$0.20
Change
-$0.00 (-0.00%)
Updated
Nov 4 closing price
YMAB
Price
$14.87
Change
+$0.36 (+2.48%)
Updated
Nov 4 closing price
3 days until earnings call
Ad is loading...

COEP vs YMAB

Header iconCOEP vs YMAB Comparison
Open Charts COEP vs YMABBanner chart's image
Coeptis Therapeutics Holdings
Price$0.20
Change-$0.00 (-0.00%)
Volume$111.71K
CapitalizationN/A
Y-mAbs Therapeutics
Price$14.87
Change+$0.36 (+2.48%)
Volume$170.92K
CapitalizationN/A
View a ticker or compare two or three
COEP vs YMAB Comparison Chart
Loading...
COEP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
COEP vs. YMAB commentary
Nov 05, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COEP is a StrongSell and YMAB is a Buy.

COMPARISON
Comparison
Nov 05, 2024
Stock price -- (COEP: $0.20 vs. YMAB: $14.87)
Brand notoriety: COEP and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: COEP: 37% vs. YMAB: 78%
Market capitalization -- COEP: $7.95M vs. YMAB: $662.75M
COEP [@Biotechnology] is valued at $7.95M. YMAB’s [@Biotechnology] market capitalization is $662.75M. The market cap for tickers in the [@Biotechnology] industry ranges from $498.83B to $0. The average market capitalization across the [@Biotechnology] industry is $2.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COEP’s FA Score shows that 1 FA rating(s) are green whileYMAB’s FA Score has 0 green FA rating(s).

  • COEP’s FA Score: 1 green, 4 red.
  • YMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, both COEP and YMAB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COEP’s TA Score shows that 5 TA indicator(s) are bullish while YMAB’s TA Score has 3 bullish TA indicator(s).

  • COEP’s TA Score: 5 bullish, 5 bearish.
  • YMAB’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, COEP is a better buy in the short-term than YMAB.

Price Growth

COEP (@Biotechnology) experienced а -3.80% price change this week, while YMAB (@Biotechnology) price change was +0.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.74%. For the same industry, the average monthly price growth was +10.27%, and the average quarterly price growth was +7.68%.

Reported Earning Dates

COEP is expected to report earnings on Mar 29, 2023.

YMAB is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (-1.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
YMAB($663M) has a higher market cap than COEP($7.95M). YMAB YTD gains are higher at: 118.035 vs. COEP (-74.474). COEP has higher annual earnings (EBITDA): -14.84M vs. YMAB (-27M). YMAB has more cash in the bank: 77.8M vs. COEP (1.56M). YMAB has less debt than COEP: YMAB (1.27M) vs COEP (1.79M). YMAB has higher revenues than COEP: YMAB (86.5M) vs COEP (0).
COEPYMABCOEP / YMAB
Capitalization7.95M663M1%
EBITDA-14.84M-27M55%
Gain YTD-74.474118.035-63%
P/E RatioN/AN/A-
Revenue086.5M-
Total Cash1.56M77.8M2%
Total Debt1.79M1.27M140%
FUNDAMENTALS RATINGS
COEP vs YMAB: Fundamental Ratings
COEP
YMAB
OUTLOOK RATING
1..100
110
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
6338
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

COEP's Valuation (27) in the null industry is in the same range as YMAB (59) in the Pharmaceuticals Major industry. This means that COEP’s stock grew similarly to YMAB’s over the last 12 months.

COEP's Profit vs Risk Rating (100) in the null industry is in the same range as YMAB (100) in the Pharmaceuticals Major industry. This means that COEP’s stock grew similarly to YMAB’s over the last 12 months.

YMAB's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as COEP (100) in the null industry. This means that YMAB’s stock grew similarly to COEP’s over the last 12 months.

YMAB's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as COEP (63) in the null industry. This means that YMAB’s stock grew similarly to COEP’s over the last 12 months.

YMAB's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as COEP (100) in the null industry. This means that YMAB’s stock grew similarly to COEP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COEPYMAB
RSI
ODDS (%)
Bearish Trend 1 day ago
45%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
58%
Bullish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
58%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
38%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 19 days ago
54%
Bullish Trend 1 day ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
75%
Bearish Trend 12 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
47%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
15%
Bullish Trend 1 day ago
84%
View a ticker or compare two or three
Ad is loading...
COEP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VLIFX35.830.10
+0.28%
Value Line Mid Cap Focused
DEVDX12.88N/A
N/A
Driehaus Event Driven
HWAIX41.15-0.01
-0.02%
Hotchkis & Wiley Value Opps Instl
NBPIX46.88-0.15
-0.32%
Neuberger Berman Large Cap Value Instl
HIOIX12.15-0.05
-0.41%
Fintrust Income and Opportunity Instl